期刊文献+

长期服用华法林抗凝患者的药学监护 被引量:10

Pharmaceutical care for patients using warfarin for long-term anticoagulation
下载PDF
导出
摘要 目的探讨临床药师对长期服用华法林患者进行药学监护的内容和模式。方法以3例长期服用华法林的患者为例,分析服药期间出现不良事件的原因,总结临床药师在华法林抗凝治疗中需重点监护的内容。结果通过实施药学监护,临床药师发现对于长期服用华法林的患者,药学监护应重点关注以下几个方面对华法林抗凝作用的影响:(1)患者疾病状态;(2)合并使用药物的影响;(3)患者是否有外科手术或者创伤性检查;(4)患者饮食习惯。结论临床药师为华法林的监护模式提供了合理化建议,并对患者进行用药教育,从一定程度上保障了华法林在临床使用过程中安全合理和有效。 Objective To determine the content and pattern of pharmacy care for patients who used warfarin for long-term anticoagulation. Methods Three patients who used warfarin for long-term anticoagulation were taken as examples. The causes of adverse events were analyzed. The contents of pharmaceutical care provided by clinical pharmacists during warfarin anticoagulation were summarized. Results Clinical pharmacists found that in long-term warfarin treatment, pharmaceutical care of warfarin anticoagulation should focus on the following aspects: (1) patient disease status; (2) combination with other drugs; (3) whether patients had surgery or traumatic examination; and (4) patient diet. Conclusion Pharmacists provided reasonable suggestions for the monitor of warfarin use to ensure its safety and effectively.
作者 许珍珍 喻俊峰 张坡 师浩 XU Zhen-zhen;YU Jun-feng;ZHANG Po;SHI Hao(The 150th Central Hospital of the People's Liberation Army, Luoyang Henan 471031)
机构地区 解放军第
出处 《中南药学》 CAS 2018年第6期860-862,共3页 Central South Pharmacy
关键词 华法林 临床药师 药学监护 抗凝治疗 warfarin clinical pharmacists pharmacy care anticoagulation
  • 相关文献

参考文献2

二级参考文献20

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2Turrentine MA. Single-dose fluconazole for vulvovaginal candidiasis: impact on prothrombin time in women taking warfarin[J]. Obstet Gynecol, 2006, 107(2 Pt 1): 310-313.
  • 3Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J]. Chest, 2008, 133(6 Suppl): 160S-198S.
  • 4Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 5Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 6Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 7Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 8Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 9Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 10Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.

共引文献607

同被引文献130

引证文献10

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部